カンファレンス

第9回フラグメントベース創薬ミーティング

カレンダー日時
  • 2024年3月3日~5日
所在地所在地
  • 英国ケンブリッジ

Schrödingerは、イギリス・ケンブリッジのヒンストン・ホールにて3月3日から5日まで開催される第9回 Fragment-based Drug Discovery Meetingに参加いたします。SchrödingerのPrincipal Scientist IであるAntonija Kuzmanicによる、「Large-scale in silico Fragment Screening Based on Absolute Free Energy Perturbation (AB-FEP+)」と題したポスター発表にご参加ください。

Title: Large-scale in silico Fragment Screening Based on Absolute Free Energy Perturbation (AB-FEP+)
Speaker:
Antonija Kuzmanic, Principal Scientist I
Abstract:
Fragment screening has witnessed remarkable success with 6 FDA approved drugs and many more in clinical trials. Here we present a computational innovation to dramatically expand the scope of fragment screening, from screening typical ~3k – 30k experimental fragment libraries to screening ~200 million fragments with high hit rates. This approach involves a virtual screening funnel based on Absolute Free Energy Perturbation to rigorously score diverse fragments based on their predicted binding affinities, allowing for only a small number of fragments (~25-50) to be purchased and/or synthesized for experimental testing. This approach has already been successfully applied during the hit finding stage for several active internal drug discovery projects, resulting in potent (nM – uM), ligand efficient (LE 0.38 – 0.51) starting points from which to initiate our discovery campaigns. In the TPL2 project, five fragments hits (<100 uM) were identified from fragment screening and were expanded to develop initial SAR, which led to discovery of the hit compounds.